Clinician territory

Psoriasis: what therapy actually involves

This one is not a self-therapy pathway, and building it as one would be dishonest. Here is what psoriasis is, why the skincare aisle is legally and practically limited to managing scale, and what the real therapy ladder looks like from the outside.

Why there is no over-the-counter pathway on this page

Every other treatment page on this site is built around a walkable chart: start here, use this properly for twelve weeks, and if it has not worked, here is the door to a prescription. That structure is honest when over-the-counter treatment is genuinely first-line for some version of the condition. For psoriasis it is not. Psoriasis is an immune-mediated disease in which the adaptive immune system drives skin cells to divide far faster than they should, and no product available without a prescription modifies that process. Drawing a self-therapy ladder here would manufacture a tier that does not exist, and its most likely effect would be delay — months spent working through an aisle while the actual treatment, which is effective and increasingly good, sits behind an appointment nobody made.

This is not editorial caution — it is what the regulation says

In the United States the over-the-counter monograph covering psoriasis products is narrow and specific. Only coal tar, at 0.5% to 5%, carries a permitted psoriasis indication. Salicylic acid is permitted in the same subpart, but its monographed indications are dandruff and seborrhoeic dermatitis rather than psoriasis. There is no over-the-counter allowance for anything that alters the underlying immune process — no corticosteroid at meaningful potency, no vitamin D analogue, nothing in the classes that actually control this disease. An over-the-counter product may legitimately help lift and soften scale. That is the ceiling, and it is drawn by regulation rather than by our opinion of the products.

21 CFR Part 358 Subpart H — Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis — US Electronic Code of Federal Regulations

What over-the-counter care genuinely does here

  • Soften and lift scale so that prescribed treatment reaches the plaque underneath, which is a genuine and underrated contribution
  • Reduce the discomfort, cracking and itch of dry plaques
  • Support the barrier between flares, with reasonable trial evidence that emollient use after a topical steroid course helps hold the improvement
  • Manage scalp scale, where medicated shampoos have a real and long-established role

What it cannot do

  • Alter the immune signalling that drives the disease
  • Clear an established plaque
  • Prevent psoriasis progressing or spreading
  • Do anything at all about the joints, which is the part that can cause permanent damage
  • Substitute for assessment when a first plaque appears — the diagnosis itself is worth confirming

None of that makes moisturiser pointless. It makes it adjunct — a genuinely useful supporting role next to a treatment, rather than a treatment wearing a supporting role's clothes. The distinction matters most for the person who has been managing alone for two years and does not know what they have been missing.

Before anything else
  • Redness and scaling spreading over most of the body, with shivering, fever or feeling very unwell Same day

    Erythrodermic psoriasis disrupts temperature regulation and fluid balance across the whole skin surface and is a medical emergency with real mortality. It needs hospital assessment the same day rather than an urgent dermatology appointment.

  • Crops of small pustules on hot red skin, with fever Same day

    Generalised pustular psoriasis is a distinct and dangerous presentation requiring immediate specialist involvement. It can be provoked by abruptly stopping oral corticosteroids, which is one of several reasons systemic steroids are avoided in psoriasis.

  • Joint pain, swelling, or morning stiffness lasting more than 30 minutes Promptly

    Psoriatic arthritis causes joint damage that does not reverse, and diagnostic delay is common and consequential. Skin treatment can wait a few weeks; this cannot. A swollen finger or toe, heel pain, or persistent low back stiffness in someone with psoriasis all warrant prompt assessment.

  • A plaque that is bleeding, ulcerating, or changing in a way the others are not Promptly

    Long-standing plaques do not usually behave differently from one another. One that does — particularly if it ulcerates or fails to heal — needs a clinician's eye rather than a stronger cream.

  • A first, undiagnosed scaly patch Worth raising

    Not an emergency, but worth stating: several conditions look like this and two of them are made worse by the standard psoriasis treatment. Getting the diagnosis right before treating hard is the highest-value appointment there is here.

What is actually happening

Psoriasis is an immune-mediated inflammatory disease that happens to be most visible in the skin. A self-sustaining loop between immune cells and skin cells — driven largely by signalling molecules in the interleukin-17 and interleukin-23 families — pushes keratinocytes to divide and migrate to the surface in a few days rather than the usual few weeks. They arrive immature and pile up, which is the silvery scale, over a dilated inflamed vasculature, which is the deep red plaque beneath it. Two things follow from that description. First, the disease is systemic rather than cosmetic: the same inflammation is measurable elsewhere in the body, which is why psoriasis travels with joint disease, cardiovascular risk and depression. Second, the treatments that genuinely work are the ones that interrupt the immune signalling — which is exactly the category that requires a prescription.

Who this page is for

Anyone recently diagnosed who wants to understand what is being offered and why; anyone with thick scaly plaques who has been managing with drugstore products and suspects there is more available; and anyone wondering whether the aching joints they have started noticing are connected. It is also for people who have read that psoriasis is incurable and concluded that means untreatable. Those are very different statements, and the gap between them has widened enormously in the last fifteen years.

This page helps you understand the landscape — it is not a diagnosis. Several conditions produce red scaly patches: eczema, which typically itches more and sits in the flexures rather than over the elbows and knees; seborrhoeic dermatitis; fungal infections, which can look strikingly similar and are made worse by the steroids used for psoriasis; and less common conditions that need recognising. Getting that distinction right is the first thing an appointment is for.

The forms it takes

Psoriasis is described by type, by how much skin is involved, and — increasingly and more usefully — by how much it affects the person who has it. That last measure matters more than it sounds: a small plaque in a visible or awkward place can be more disabling than extensive disease on a back, and current guidance recognises site and impact rather than surface area alone when deciding how aggressively to treat.

Plaque psoriasis

The commonest form by a wide margin — well-demarcated raised plaques with silvery scale.

Symmetrical, sharply edged plaques over the elbows, knees, lower back and scalp, deep red or violaceous under a layer of loose silver-white scale. On deeper skin tones the redness reads as purple, grey or dark brown, and psoriasis is under-recognised on that basis.

Guttate psoriasis

A sudden shower of small teardrop-shaped spots, classically a week or two after a sore throat.

Dozens or hundreds of drop-sized scaly papules scattered across the trunk and upper arms, arriving over days rather than months, most often in children and younger adults. Streptococcal throat infection is the recognised provocation, which is why a throat swab or a blood test for recent streptococcal infection is part of the assessment. Many episodes settle on their own over some months; some recur, and a proportion of people later develop the plaque form. Because the spots are small, numerous and everywhere, creams are impractical as the main treatment here — light treatment has traditionally been the answer, and short courses of newer drugs are increasingly used.

Scalp, nail, flexural and genital involvement

Sites where psoriasis behaves differently, is treated differently, and is disproportionately distressing.

Thick adherent scalp scale along the hairline; nails that are pitted, thickened or lifting from the bed; smooth shiny plaques without scale in skin folds; genital involvement that people very frequently do not mention unless asked. Nail and scalp disease both carry a higher associated likelihood of joint involvement, which makes them worth reporting rather than tolerating.

Extensive or treatment-resistant disease

Widespread involvement, or disease that has not responded to properly used topical treatment.

Large areas of the trunk and limbs involved. This is the presentation where phototherapy, conventional systemic drugs and biologics are the relevant conversation, and where continuing with creams alone is the main way people lose years.

Erythrodermic and generalised pustular psoriasis

Rare, acute presentations that are medical emergencies rather than severe versions of ordinary psoriasis.

Erythrodermic: redness and scaling over most of the body surface, with disturbed temperature regulation, fluid loss and systemic illness. Generalised pustular: crops of sterile pustules on hot red skin with fever and feeling profoundly unwell. Both need urgent hospital assessment, and neither is something to manage at home. One thing has changed for the better here: an antibody aimed at a signalling receptor specific to the pustular form was approved for these flares and settles the pustules within days, in a presentation that until recently had no treatment developed for it at all.

What changes the picture

Joint symptoms
Psoriatic arthritis develops in roughly one in five to one in three people with psoriasis, and unlike the skin disease it can cause permanent, irreversible joint damage. It also frequently goes undiagnosed for years. This changes the entire calculus of the page: skin treatment can reasonably be taken at your own pace, and joint symptoms cannot. Morning stiffness lasting over half an hour, a swollen finger or toe, heel pain or persistent lower back stiffness are all worth raising promptly.
Cardiovascular and metabolic risk
Psoriasis is associated with a higher risk of cardiovascular disease, hypertension, diabetes and dyslipidaemia, and current joint dermatology guidance specifically recommends that people with psoriasis be educated about that risk and screened for those conditions. It reframes what the appointment is for — the skin is the visible part of something being managed more broadly.
Mood and psychological impact
The association with depression, anxiety and suicidality is established in large population data and scales with severity. This is not incidental to the disease and it is a legitimate reason to treat more assertively, which is a point worth making explicitly at an appointment if quality of life is the main thing being affected.
Recognised triggers
Streptococcal throat infection, certain drugs including lithium, beta-blockers and antimalarials, skin injury, smoking, heavy alcohol use and stress can all provoke or worsen psoriasis. Skin injury in particular produces new plaques at the site — which is why scrubbing or picking a plaque reliably makes it larger. The most consequential of these is not a trigger for an ordinary flare: stopping a course of steroid tablets can tip stable psoriasis into its whole-body or pustular form, which is why those tablets are generally kept away from this condition even though they work in the short term.
Pregnancy and planning a pregnancy
Several systemic treatments are strictly contraindicated in pregnancy, and one of them requires contraception for an extended period after stopping. This is a conversation to have before conceiving rather than after, and it is one of the clearest reasons to be under a clinician's care rather than managing alone.

What else looks like this

Eczema
Usually itchier, less sharply demarcated, and favours the inside of elbows and behind the knees rather than the outside of them. The two can look similar enough that a biopsy is occasionally used to settle it.
Fungal infection
Often has an advancing scaly edge with clearing in the middle. It matters enormously that this is distinguished, because the steroids used for psoriasis make a fungal infection substantially worse.
Seborrhoeic dermatitis
Greasier, yellower scale in the brows, nasolabial folds and scalp. Scalp psoriasis and seborrhoeic dermatitis overlap so often that there is a recognised in-between presentation.
Cutaneous lupus and other inflammatory conditions
Several less common conditions produce scaly plaques and need distinguishing by someone who sees them regularly. This is one of the reasons a first plaque is worth showing to a clinician rather than treating from a photograph search.

The single most useful thing you can do before an appointment is not to have started a strong steroid cream on it. Partially treated psoriasis is considerably harder to identify, and a fungal infection treated with steroids can be transformed into something quite unlike either. If a plaque is new and undiagnosed, moisturiser is a safe holding position and almost nothing else is.

What therapy actually involves

What follows describes what treatment involves. It is deliberately not a ladder you climb yourself, and it contains no doses — the point is to make an appointment legible, so that what is offered makes sense and you know which questions are worth asking.

Which tier is appropriate depends on how much skin is involved, where it is, how much it affects your life, what other conditions you have, and what you have already tried. Current joint guidance is explicit that there is no single best treatment and no fixed order for everyone — selection is individualised, and that is a real clinical judgement rather than a hedge.

  1. Prescription topicals

    The starting point for limited disease and the mainstay for most people, and the tier that has changed most recently. Corticosteroids of a potency matched to the site and vitamin D analogues remain the backbone — frequently as a fixed combination of both in one product, which outperforms either on its own — and two non-steroid creams approved in 2022 have since given prescribers something for the sites where steroids are awkward to keep using.

    • Topical corticosteroids backed by large randomized trials Potency is matched to the site: what is appropriate for an elbow is not appropriate for a face or a fold. Strong ones are prescribed in defined bursts rather than continuously, then dropped to an intermittent rhythm.
    • Vitamin D analogues (calcipotriol/calcipotriene, calcitriol, tacalcitol) backed by large randomized trials Slow the excessive cell turnover. There is more than one, and they differ in how much they sting — which is the reason a prescriber may switch between them rather than abandon the class, particularly for the face and folds.
    • Fixed steroid + vitamin D combinations backed by large randomized trials One application instead of two, in foams, gels and ointments. The foam formulation is the one most of the recent trial evidence sits behind, including the twice-weekly maintenance schedule described further down this page.
    • Tapinarof cream backed by large randomized trials An aryl hydrocarbon receptor agonist, FDA-approved for plaque psoriasis in adults in May 2022 — the first genuinely new topical chemistry for psoriasis in the US in decades. Folliculitis is the side effect it is known for; irritation notably is not.
    • Roflumilast cream backed by large randomized trials A topical PDE4 inhibitor, FDA-approved in July 2022, and one that performed better in skin folds than on ordinary plaques in its trials — the reverse of the usual problem, and the reason it matters at exactly the sites steroids cannot be used indefinitely.
    • Topical calcineurin inhibitors (tacrolimus, pimecrolimus) backed by smaller studies Not licensed for psoriasis, and used for it anyway on the face and in folds, where their lack of any thinning effect is worth more than the extra potency a steroid would bring. On thick plaques elsewhere they underperform.
    • Topical retinoid (tazarotene) backed by large randomized trials Effective and irritating in roughly equal measure, which is why it is often paired with a steroid rather than used alone, and why it is generally kept away from genital skin.
    • Corticosteroid injected into the plaque backed by smaller studies For a small number of stubborn plaques or nails that have not answered anything applied on top — a targeted step rather than an escalation of the whole plan.
    What to expect
    Improvement over weeks rather than days, with plaques flattening before the colour fades. The residual brown or pale marks left behind are not active disease and need no treatment. Roughly two thirds of the work here is done by using enough, for long enough, on skin that has been descaled first.
    Who it's for
    Limited disease, and alongside every tier above as needed.
    What gets monitored
    No laboratory monitoring for any of this. What is watched is the skin itself, at the sites where potent steroids do damage — thinning, stretch marks and visible surface vessels on the face, in folds and on genital skin — which is the reason the strong ones come with a stated number of weeks attached.
    In pregnancy
    Several topicals are used in pregnancy with appropriate care, and the choice and the amount both change. This is decided with a clinician rather than assumed.

  2. Phototherapy

    Controlled exposure to ultraviolet light in a clinic, usually two or three times a week for a course of weeks. It is the medical version of the thing many people notice on holiday, with the crucial differences that the wavelength is narrowed to the part that treats psoriasis, the dose is measured, and the total exposure is recorded over a lifetime. It carries no systemic drug exposure, which keeps it valuable for anyone who cannot or would rather not take a medicine.

    • Narrow-band UVB backed by large randomized trials The standard modality, and the most consistently highly graded in current guidance.
    • PUVA (a light-sensitising drug plus UVA) backed by large randomized trials Clears more people than narrow-band UVB in head-to-head trials, in fewer sessions, and the remissions last longer. It is used far more selectively than it once was because the cumulative skin cancer risk is real, and it is avoided altogether in anyone who has already had one.
    • Targeted phototherapy (excimer laser) backed by smaller studies Aims the same light at a few stubborn areas instead of the whole body — useful for palms, soles and single plaques that outlast everything else.
    • Home units backed by smaller studies Narrow-band UVB cabinets and hand-held or comb-shaped devices for the scalp exist and are supervised remotely; availability varies enormously by country and by insurer.
    What to expect
    A real time commitment — repeated clinic visits over a couple of months — which is its main practical drawback rather than any lack of effectiveness. A course ends rather than continues indefinitely, and how long the improvement holds afterwards varies from a few months to considerably longer.
    Who it's for
    Extensive disease, or where systemic treatment is unsuitable or unwanted.
    What gets monitored
    Cumulative lifetime dose is tracked, unaffected skin is covered and eyes are protected during treatment, and skin checks become part of the picture with the light-sensitising form in particular. A course is also often paired with a low dose of an oral retinoid, which lets the same result be reached with meaningfully less light.
    In pregnancy
    Narrow-band UVB is generally regarded as compatible with pregnancy and is often the preferred option when treatment beyond creams is needed. The light-sensitising tablet used in PUVA is not part of that answer.

  3. Conventional systemic drugs

    Tablets and injections you take yourself, in two distinct groups. The long-established drugs suppress or modulate immunity broadly and need regular blood monitoring; the newer ones interrupt a single signalling step and need much less. All of them are chosen with your other health conditions firmly in view, which is why the history matters more than the rash at this point.

    • Methotrexate backed by large randomized trials Long-established and taken weekly rather than daily. Liver effects are what the monitoring exists for, and existing liver disease or heavy alcohol use can rule it out.
    • Acitretin backed by smaller studies A retinoid, modest on its own and considerably more useful combined with light treatment. It requires contraception for an extended period after the last dose, and it is one of the few drugs here that lowers rather than raises skin cancer risk.
    • Ciclosporin backed by large randomized trials Fast — the option when something has to change quickly. Kidney function and blood pressure are the limits, and guidance caps how long it is used continuously rather than leaving anyone on it indefinitely.
    • Apremilast backed by large randomized trials An oral PDE4 inhibitor with modest results and an unusually light monitoring burden; digestive upset and weight loss early on are what people notice.
    • Deucravacitinib backed by large randomized trials The newest of the tablets, blocking a single enzyme (TYK2) inside the signalling pathway rather than damping immunity across the board. Its trials ran against apremilast and placebo over a full year.
    What to expect
    Regular review, and for the older drugs regular blood tests. That monitoring is the trade being made, and it is a reasonable one for disease that is genuinely affecting your life. Combining two of these at low doses, or rotating between them over years, is a deliberate strategy for keeping the cumulative exposure to any one drug down — not a sign that something has gone wrong.
    Who it's for
    Moderate to severe disease, or disease unresponsive to topical treatment and phototherapy.
    What gets monitored
    Blood tests before starting and at intervals afterwards, and what is checked differs by drug: blood counts and liver for methotrexate, kidney function and blood pressure for ciclosporin, cholesterol and triglycerides for acitretin, comparatively little for the two newest tablets. Screening for tuberculosis and viral hepatitis is usual before anything that suppresses immunity.
    In pregnancy
    This is the tier where pregnancy planning matters most. Methotrexate and acitretin are strictly contraindicated, and acitretin's contraception requirement extends for a long period after the last dose. Anyone who might become pregnant should raise this before starting, not after.

  4. Biologics

    Injected antibodies that block a specific signalling molecule in the pathway driving psoriasis, rather than suppressing immunity broadly. This is the category that has transformed outcomes over the last fifteen years, and it is the reason 'incurable' and 'untreatable' have come so far apart.

    • TNF inhibitors backed by large randomized trials The earliest class in psoriasis and still widely used, particularly where joint disease is present. Latent tuberculosis reactivating is the specific risk they are screened for.
    • IL-17 inhibitors backed by large randomized trials Fast — often the class chosen when the situation needs to change quickly. Some newer agents block two members of the family rather than one, and the highest clearance figures published so far belong to that group. Thrush is the side effect they are known for.
    • IL-23 inhibitors backed by large randomized trials Target the pathway further upstream. Slower to take effect than the IL-17 class and dosed as infrequently as every two to three months once established, which is why they suit people whose disease is stable rather than galloping.
    • IL-12/23 inhibition backed by large randomized trials An earlier approach to the same pathway, still in use, and the one with the longest accumulated safety record among the newer classes.
    What to expect
    Screening before starting — tuberculosis and hepatitis among other things — then injections at intervals from fortnightly to every few months depending on the agent. Response is frequently dramatic compared with earlier tiers, and complete clearance is now a stated goal in trials rather than an outlier.
    Who it's for
    Moderate to severe psoriasis that has not responded adequately to other treatment, and often earlier where psoriatic arthritis is also present. Access is commonly governed by funding criteria that specify what must be tried first.
    What gets monitored
    Tuberculosis and hepatitis screening before the first dose, then far less routine blood work than the older tablets require. Vaccinations are worth settling in advance: non-live vaccines are given as normal on almost all of these treatments, while live ones need planning around the drug.
    In pregnancy
    Decisions about biologics in pregnancy are individualised and are made jointly between dermatology and obstetric care. Some are continued where the benefit justifies it; none of this is a decision to take from a web page.

Where it is changes what is used

Extent decides the tier; site decides the prescription. The same disease on an elbow, a scalp and a fold gets three different products, and someone who has only ever been given one cream for all of them is usually being under-treated somewhere.

Scalp
Ointments and creams are unusable in hair, so scalp treatment arrives as gels, foams, sprays, solutions and medicated shampoos instead. Thick adherent scale is softened first, because medicine applied on top of a crust treats the crust. Tar and salicylic acid shampoos have a genuine adjunct role at this one site, and a persistent patch is sometimes injected rather than escalated to a tablet.
Face
Thin skin thins further under strong steroids, so potency drops sharply here and the milder ones are alternated with something else rather than run continuously. This is the site where the non-steroid creams — the two approved in 2022 and the older calcineurin inhibitors used off-label — earn their keep, because they can be used for long stretches without that cost.
Folds and genital skin
Plaques here are smooth, shiny and often have no scale at all, which is exactly why they get mistaken for a fungal infection or ordinary chafing. Steroid caution matches the face, some vitamin D analogues sting in a fold while others are tolerated, and retinoid creams are usually too irritating for genital skin. Genital involvement is common, almost never volunteered, and answers well once it has been named.
Palms and soles
A tiny share of body surface and one of the most disabling places to have it, because walking and using your hands are what it costs. Thick palm and sole skin also blunts what a cream can reach. This is the classic situation where light treatment or a tablet is appropriate despite very little total skin being involved, and where treatment answers more slowly than it does elsewhere.
Nails
Nails grow slowly, so nail psoriasis is judged over months rather than weeks and needs patience that the rest of the disease does not. It is also one of the features associated with joint involvement, which is a better reason to mention it at an appointment than how it looks.

It is why the answer to 'how bad is it' is never only a percentage. Guidance recognises site and impact alongside extent, and a small area in a difficult place routinely justifies treatment that a larger area on a back would not.

No doses appear on this page, deliberately, and no ranking of one option against another. Which of these fits is a clinical judgement made with your full history in front of the person making it — and for several of these drugs, what is funded where you live shapes the answer as much as what is ideal.

What else gets looked for

The most important thing on this page is not a treatment. Psoriasis travels with several conditions that matter more than the skin does, and the appointment is where they get looked for.

Psoriatic arthritis

Develops in a substantial minority of people with psoriasis — commonly cited at around a fifth to a third — and in most cases the skin disease comes first, which means people with psoriasis are the group worth watching. Unlike plaques, damaged joints do not recover.

At an appointment: A clinician asks about morning stiffness, swelling and heel or back pain, examines the joints, and refers to rheumatology if there is a suspicion. Nail psoriasis and scalp involvement are both associated with a higher likelihood, so they are worth mentioning.

Cardiovascular and metabolic disease

Psoriasis carries an increased risk of cardiovascular disease, hypertension, diabetes and abnormal lipids, and current joint guidance recommends that this be discussed and screened for rather than left to chance.

At an appointment: Blood pressure, lipids and glucose checked at appropriate intervals — earlier and more often with more extensive disease or systemic treatment. Ordinary preventive medicine, prompted by the skin.

Depression and anxiety

Large population data show a clearly raised risk of depression, anxiety and suicidality in people with psoriasis, rising with severity. It is a recognised part of the disease rather than a personal failing, and it is a legitimate argument for treating the skin more assertively.

At an appointment: It gets asked about, and it should. If quality of life is what the disease is mainly damaging, saying so plainly is often what changes which treatment tier is considered.

Inflammatory bowel disease and other immune conditions

Psoriasis shares mechanisms with several other immune-mediated conditions, and their presence can influence which treatment is chosen — some agents treat both, and a few are unsuitable where bowel disease coexists.

At an appointment: Worth mentioning any bowel symptoms or other immune diagnoses, because it genuinely changes the shortlist.

None of this is a reason for alarm, and it is emphatically not a list of things that will happen. It is the reason the appointment is worth making even when the skin itself feels manageable — these are the parts a moisturiser cannot address and a clinician can.

When the rules change

Everything above describes an adult who is not pregnant, has no competing diagnosis and could in principle be offered anything. Four groups where that assumption breaks — and where the answer is a different list rather than an empty one.

Pregnancy, breastfeeding, and planning either

Psoriasis itself behaves unpredictably in pregnancy: it improves for many people and worsens for a minority. The treatment list changes far more than the disease does, and the timing of the conversation matters — two of the oral drugs need planning months ahead rather than a decision taken at a positive test.

What stays open

  • Emollients and scale-softening, without restriction and at any stage
  • Topical corticosteroids, with both the site and the total quantity considered — how much is used over how large an area is the part that changes here
  • Narrow-band UVB, frequently the preferred option when treatment beyond creams is needed
  • Certain biologics, continued or started where the benefit justifies it, decided jointly by dermatology and the obstetric team rather than by either alone

What comes off the table

  • Methotrexate — contraindicated, and stopped well ahead of conception rather than at the first positive test
  • Acitretin — contraindicated, and carrying the contraception requirement that runs for a long period after the last dose, which is why it is rarely the choice for anyone who might become pregnant
  • The light-sensitising tablet used in PUVA
  • Unlimited use of potent steroids across large areas, which is a quantity question rather than an outright ban

A sudden severe pustular presentation occasionally appears in pregnancy. That is a same-day hospital matter rather than a treatment decision, and it is one of the reasons the red flags at the top of this page are worth reading twice.

Children and teenagers

Psoriasis in childhood is not a smaller version of the adult disease. The drop-shaped guttate pattern after a throat infection is far more common here, plaques are often thinner, and the joint association still applies. There is a dedicated paediatric guideline in the same series as the adult ones, which is worth knowing exists when a treatment is being discussed for a child.

What stays open

  • Emollients and gentle descaling, which do the same job at any age
  • Topical corticosteroids at a potency and quantity calculated for a smaller body, usually alongside a vitamin D analogue
  • Narrow-band UVB for widespread disease, where a child can manage the cabinet
  • Several biologics, which are licensed for children and adolescents with age thresholds that differ by drug and by country

What comes off the table

  • Scaling an adult's regimen down by eye — potency, area and amount are all recalculated, and a strong adult steroid on a child is a genuine problem rather than a caution
  • Treating a sudden shower of small spots as an ordinary flare without the throat being considered

The other thing paediatric guidance is explicit about is that the burden is not proportional to the surface area. School, sport and swimming come into the decision, and saying so is legitimate rather than fussy.

A history of skin cancer, or a lot of accumulated sun damage

This is the clearest example of a personal history reshuffling the list rather than shortening it, and it is worth raising unprompted at a first appointment because it changes what should be offered from the start.

What stays open

  • Acitretin, which is actively chosen in this situation — it suppresses the development of new skin cancers rather than encouraging them
  • The IL-17 and IL-23 classes, which have not shown an increase in malignancy in their accumulated data
  • Narrow-band UVB, with cumulative dose tracked and skin checks kept up

What comes off the table

  • PUVA, whose cumulative skin cancer risk is well documented and is the main reason its use has fallen
  • Long-term ciclosporin, which raises the same risk over years of continuous use

Nothing here means treating the psoriasis less. It means the ordinary first choices move down the list and other perfectly effective ones move up.

Screening, infections and vaccinations

Everything that damps immunity comes with a short list of things checked first, and none of it is a barrier — it is scheduling. Knowing it is coming makes the gap between deciding on a treatment and starting it far less mystifying.

What stays open

  • Non-live vaccines, given as normal on almost all of these treatments — the consensus advice is to keep them up rather than skip them, with methotrexate briefly held around the dose
  • Live vaccines, planned deliberately: given before treatment starts where any are due, or with the drug paused around them under specific guidance
  • Prompt treatment of a streptococcal throat infection, which matters more here than in most people given the guttate link

What comes off the table

  • Starting an immune-targeted treatment without tuberculosis and hepatitis screening, which is standard before biologics, methotrexate and ciclosporin alike
  • Arranging a live vaccine while on one of these drugs without checking the interval first

If a course of treatment is being planned around a trip that needs travel vaccinations, that is worth raising early — the sequencing is easy in advance and awkward afterwards.

Over the counter — everyday support, not therapy

Where products do help

Nothing over the counter treats psoriasis. At all. The products in this section are here for the everyday upkeep of skin that happens to have psoriasis — keeping it comfortable, supported and un-irritated around the therapy that does the work. None of them improves the condition itself, and none of them is a reason to delay the appointment.

Here is where over-the-counter products genuinely earn their place. Not as treatment, and not as a substitute for one — as the thing that makes prescribed treatment work better and daily life more comfortable.

The job of everything here is to soften scale, keep the barrier intact, and avoid provoking new plaques. Psoriasis exhibits the Koebner phenomenon — new plaques appear where skin has been injured — which makes scrubbing, picking and aggressive exfoliation genuinely counterproductive rather than merely unhelpful.

Worth doing

  • Moisturise generously and often, especially straight after bathing while skin is still damp
  • Use thick ointments and creams over lotions on plaques; the greasier ones hold water better and soften scale faster
  • Soften scale before applying a prescribed topical, so the medicine reaches the plaque rather than the crust on top of it
  • Keep baths and showers short and lukewarm, and pat rather than rub afterwards
  • Consider a medicated shampoo for scalp scale, which is the one site where over-the-counter treatment has a long-established role
  • Keep emollients going between flares — there is trial evidence that emollient use after a topical steroid course helps hold the improvement

Worth avoiding

  • Scrubbing, picking or forcibly removing scale, which reliably produces new plaques at the site
  • Fragranced products on cracked or fissured skin
  • Long hot baths, which feel wonderful and leave skin drier
  • Treating an undiagnosed scaly patch with a strong steroid cream borrowed from someone else
  • Stopping a prescribed treatment abruptly without saying so — with systemic corticosteroids in particular this can provoke a severe flare, which is why they are generally avoided in psoriasis

Product categories that fit that job

A supporting product's job here is to not interfere with what is actually treating this — gentle, fragrance-free, unexciting on purpose. Each link opens the full, always-current listing for that shelf.

An emollient for everywhere Browse all moisturizers →

A barrier moisturizer Browse all moisturizers →

A gentle cleanser Browse all cleansers →

An occlusive to seal at night Browse all moisturizers →

The National Psoriasis Foundation Seal of Recognition

The NPF operates a seal programme for non-prescription products, awarded on submitted independent testing and reviewed by a panel including dermatologists, rheumatologists and people living with the disease. Worth understanding precisely: it certifies that a product is non-irritating and suitable for psoriasis-affected skin, and it explicitly does not claim therapeutic efficacy. In other words even the disease foundation's own product programme stops short of calling these things treatment — which is the argument of this whole page, made by the people best placed to make it.

See the directory

What to expect

Psoriasis is a long-term condition that is controlled rather than cured, and the honest framing is that it comes and goes across a lifetime with periods of near-clearance and periods of flare. What has changed radically is what control looks like. Fifteen years ago, substantial improvement was a realistic ceiling for severe disease; with current biologics, complete or near-complete clearance is an ordinary treatment goal for many people. That is worth knowing if your impression of psoriasis was formed by an experience of it a decade or more ago, or by a relative's. The other half of the honest framing is that treatment is a relationship rather than a course — reviewed, adjusted, sometimes switched when a drug loses effect over years.

  • Topical treatment is under-used far more often than over-used — people apply too little, too briefly, and conclude it failed
  • Stopping the moment the skin looks good is the commonest way a good result is cut short — most plans step down rather than stop
  • Softening scale before applying a prescribed topical measurably improves what reaches the plaque
  • Marks left where plaques were are not active disease and do not need continued treatment
  • Joint symptoms are the thing to report promptly, whatever the skin is doing
  • If a treatment is not working or not tolerable, say so early — there are more options now than at any previous point, and persisting quietly with something ineffective is the costliest habit here

What happens when it works

Clearing is the start of the second half, not the end of the story, and each tier hands over differently. Topical treatment steps down rather than stops: a randomised trial of twice-weekly application to the sites that keep relapsing kept people in remission substantially longer than stopping when the skin looked clear, which is the single most useful thing on this page for anyone whose psoriasis keeps returning to the same three places. A phototherapy course ends, and the improvement holds for a variable number of months. Tablets and injections generally continue, reviewed as you go — and occasionally a drug that worked beautifully loses its grip after some years, at which point switching within or between classes is a routine event rather than a failure. Meanwhile the flat brown or pale marks left where plaques were fade on their own schedule and need nothing done to them.

Worth going back if plaques are not responding to what was prescribed, if new joint symptoms appear, if the disease is spreading, if psoriasis is affecting your mood or your sleep, or if you are planning a pregnancy while on any systemic treatment.

Getting seen

In most systems this starts with a family doctor or GP, who can diagnose psoriasis, prescribe topical treatment, and — importantly — screen for the associated conditions. Referral to dermatology is usual where the diagnosis is uncertain, where topical treatment has not controlled things, where disease is extensive or in an awkward site, or where phototherapy, systemic drugs or biologics are being considered. Rheumatology referral is separate and is prompted by joint symptoms rather than by skin severity. Access to biologics is generally governed by explicit funding criteria that specify what has to be tried first, which is worth asking about early so the sequence is not a surprise.

Worth bringing

  • Photographs of the plaques at their worst, since psoriasis fluctuates and a good day misrepresents it
  • A note of which areas are involved — including scalp, nails and genital skin, which people routinely leave out
  • A body surface area percentage — paint it on the site's BSA calculator; under 3%, 3–10% and over 10% is the severity language the appointment will be conducted in
  • Any joint symptoms, however minor they seem, and when they are worst during the day
  • What has been tried, for how long, how much was used, and what happened
  • Other conditions and all current medicines, some of which can provoke psoriasis
  • An honest account of how much it is affecting your life, which legitimately influences the treatment tier

Worth asking

  • How much of my skin is involved, and does the site change what is appropriate?
  • Should I be screened for psoriatic arthritis, and what symptoms should send me back?
  • What cardiovascular and metabolic screening should I be having, and how often?
  • What am I aiming for with this treatment — improvement, or clearance?
  • How long before we judge whether this is working?
  • If this does not work, what is next, and what has to be documented before I can access it?
  • Does anything here need to change if I plan a pregnancy?
  • If this works, what does staying on it look like — do I stop, step down, or keep going?

Cost and access

Topical treatment is generally inexpensive and widely available, though fixed-combination products and the newer non-steroidal topicals cost considerably more and are not always reimbursed. Phototherapy is usually funded where available, and its real cost is time rather than money. Biologics are expensive and access is typically gated by criteria specifying prior treatment failures and a severity threshold — which is why documenting what has been tried, and how thoroughly, matters more here than almost anywhere else on this site.

A family doctor can diagnose psoriasis, prescribe topical treatment and run the comorbidity screening, and for limited disease that may be the whole of it. Asking for dermatology referral is reasonable where topical treatment has not worked, where disease is extensive or in a difficult site, or where it is materially affecting your life. Asking about joints is reasonable at every appointment, and worth doing even if nobody raises it.

Finding a clinician

How you reach specialist care varies by country, and for psoriasis the referral route matters more than usual because access to the higher treatment tiers runs through it.

  • US Find a Dermatologist — American Academy of Dermatology

    Board-certified dermatologists searchable by location and by condition treated.

  • US Psoriasis resources and patient navigation — National Psoriasis Foundation

    Includes a free patient navigation service for questions about access, insurance and treatment.

  • UK Psoriasis — NHS overview — NHS

    Covers diagnosis, treatment tiers and when a GP should refer to a specialist.

  • Canada Find a Dermatologist — Canadian Dermatology Association

    Certified dermatologists by city or postal code; a family doctor's referral is usually required.

  • Australia Psoriasis — healthdirect — healthdirect Australia

    Government-funded information covering treatment options and when to seek care.

Regions appear only where a directory or national health service page could be verified directly. Absence reflects what we could confirm rather than what exists.

Tools that help here

Ours, free, and account-free. The first one is the most useful on this page by a distance — not knowing how much topical treatment to apply is the commonest reversible reason it appears not to work.

  • Fingertip Unit Calculator

    Prescribed topicals in psoriasis are under-applied far more often than over-applied, and the fingertip unit is the standard clinical way of describing how much is actually meant. This converts it into a number for the area you are treating.

  • BSA Calculator

    Paint your plaques on a body map and get the percentage extent is graded with: under 3% mild, 3–10% moderate, over 10% severe. Half the systemic-therapy conversation is that one number, and you can arrive with it already measured.

  • PASI Calculator

    The severity index every psoriasis trial reports, self-assessed. Your clinician will score their own in the room — but a tracked series of yours shows what happened between appointments, which no single examination can.

  • Psoriatic Arthritis Screen (PEST)

    Up to a third of people with psoriasis develop joint disease, and the skin usually comes first. Five yes/no questions, validated; three or more is the referral threshold. A positive PEST is precisely the kind of information that changes what an appointment is about.

  • Flare Diary

    Psoriasis fluctuates, and appointments have a way of landing on good days. A record of what the skin has actually been doing between visits is worth more than any description reconstructed in a waiting room.

  • Patch Test Timer

    Cracked and fissured skin reacts to things intact skin does not, which makes testing a new emollient on a small area before committing more useful here than usual.

  • Pregnancy-Safe Checker

    Useful for the supporting-care layer. It does not cover prescription treatment, which is the part that genuinely matters in pregnancy here and belongs with a clinician.

Things people ask about

Psoriasis attracts more folk remedies than most conditions, partly because it is visible and partly because it waxes and wanes on its own — which makes almost anything look like it worked once. Here is where the common questions actually stand, including the ones that hold up.

  • Sunshine, and sunny holidays backed by smaller studies

    Real, and the observation medical phototherapy was built on. Studied most formally at the Dead Sea, where a few weeks of graduated sun and bathing produced substantial clearance and remissions measured in months. Two caveats travel with it: burning provokes new plaques rather than helping, and a holiday is not a dose you can repeat at home.

  • Commercial sunbeds limited evidence

    Not the same treatment in a cheaper package. A sunbed's output is broad and weighted towards the tanning end rather than narrowed to the wavelength that treats psoriasis, nothing is measured, and the skin cancer risk is established. Sunlight helping is a good argument for asking about phototherapy, not for buying a course.

  • Coal tar preparations backed by smaller studies

    The one over-the-counter class that carries a permitted psoriasis indication at all, and it is not a token one — tar has a long record for scale and scalp disease. It smells, stains and is tedious to use, which is why it faded rather than because it stopped working.

  • Salicylic acid for descaling backed by smaller studies

    Its job is the scale rather than the disease, and it does that job well enough that it improves what a prescribed treatment can reach. Worth keeping in proportion: the evidence supports it as preparation, and none of it says the plaque underneath is being treated.

  • Cutting out gluten or nightshades limited evidence

    Without coeliac disease there is no good evidence that either elimination helps, and restrictive eating carries costs of its own — social, nutritional, and the quiet toll of believing a flare was your fault for eating a tomato.

  • Weight loss where there is weight to lose backed by smaller studies

    One of the few lifestyle measures with trial support, both for the psoriasis itself and for how well some systemic treatments work. It is slow and it is not a substitute for treatment, but unlike most of this list it has something behind it.

  • Stopping smoking and moderating alcohol backed by smaller studies

    Both are associated with more severe disease and poorer response, and alcohol additionally narrows which tablets are safe to use. Unglamorous, and among the few things on this list a person can do that reliably changes the picture.

  • Oral vitamin D supplements limited evidence

    A reasonable-sounding leap from the fact that vitamin D analogues applied to the skin work, and the trials do not support it. Worth taking for the ordinary reasons anyone takes it; not worth taking as psoriasis treatment.

  • Aloe, tea tree and turmeric preparations limited evidence

    Thin and inconsistent evidence across small studies. The pragmatic view: if one of them is comfortable on your skin it can sit alongside the treatment as a moisturiser would, and none of them earns a delay in getting the diagnosis or the prescription.

Questions people actually ask
Is psoriasis curable?

No, and that word does a lot of damage when it is heard as 'untreatable'. Psoriasis is a long-term immune-mediated condition that is controlled rather than eliminated, and for many people control now means skin that is clear or nearly so. The gap between 'incurable' and 'untreatable' has widened enormously since biologics arrived, and someone whose impression of psoriasis was formed fifteen years ago is working from an out-of-date picture.

Can I treat psoriasis with over-the-counter products?

You can manage scale and dryness with them, and that is genuinely worth doing — but you cannot treat the disease. In the United States the over-the-counter monograph permits only coal tar to carry a psoriasis indication at all, and nothing available without a prescription touches the immune signalling that drives it. Emollients and salicylic acid preparations make prescribed treatment work better by softening what sits on top of the plaque. That is a real contribution and it is not the same as treatment.

Is it contagious?

Not at all, in any way, by any route. Psoriasis is an immune-mediated disease, not an infection, and no amount of contact transmits it. This is worth stating plainly because it remains one of the most common misconceptions people with psoriasis encounter, and the social cost of it is a genuine part of the burden of the disease.

Why do my joints ache?

It may well be connected, and it is the single most important thing on this page to act on. Psoriatic arthritis affects a substantial minority of people with psoriasis, usually appearing after the skin disease, and it causes joint damage that does not reverse. Morning stiffness lasting more than half an hour, a whole finger or toe swelling, heel pain, or persistent low back stiffness are the patterns to report. Skin treatment can wait a few weeks; this should not.

Will sunbeds help? Sunlight seems to.

Sunlight often does improve psoriasis, which is precisely why medical phototherapy exists — but a commercial sunbed is not a substitute for it. Medical narrow-band UVB delivers a specific, controlled wavelength at a measured dose with cumulative exposure tracked; a sunbed delivers a broad, largely UVA output aimed at tanning, with a well-established skin cancer risk and none of the dose control. If light helps your psoriasis, that is a good reason to ask about phototherapy rather than a reason to buy a course of sunbeds.

Should I cut out gluten or nightshades?

There is no good evidence that eliminating either helps psoriasis in people without coeliac disease, and restrictive diets carry their own costs. What does have support is less dramatic: not smoking, moderating alcohol, and — where relevant — weight management, which has reasonable evidence for improving both psoriasis and the response to some treatments. Those are unexciting recommendations, and they are the ones with something behind them.

Does stress cause it?

Stress is a well-recognised trigger for flares, and it is not the cause. Psoriasis has a substantial genetic component and a specific immunological mechanism, neither of which is created by stress — but the relationship is real and it runs both ways, since having visible psoriasis is itself stressful. Managing stress is reasonable and worthwhile; being told the condition is caused by it is neither accurate nor fair.

It's only on my scalp and my palms — does that count as mild?

Not necessarily, and this is one of the most useful things to know before an appointment. Extent gets measured, but guidance weighs site and impact alongside it. Scalp, face, palms, soles, nails and genital skin are all places where a small measured area justifies treatment that the same area on a back would not, because of what it costs you in walking, working, sleeping and being looked at. Palm and sole disease in particular is notoriously hard to shift with creams and is a recognised reason to consider light treatment or a tablet despite very little total skin being involved.

Will I need blood tests for this?

It depends entirely on the tier, and it is a fair question to ask while choosing between two options. Creams and light treatment need none. The older tablets each have something specific watched — blood counts and liver, or kidney function and blood pressure, or cholesterol — usually before starting and then at intervals. The newest tablets need considerably less. Injected treatments are screened for tuberculosis and hepatitis before the first dose and then need relatively little ongoing monitoring, which surprises people who assume the newest treatments must be the most closely watched.

Can I get steroid tablets to knock a bad flare on the head?

This is one of the few places on this site where the answer is a flat no rather than a discussion. Oral corticosteroids do settle psoriasis quickly, and coming off them can tip it into a far more severe form — both of the emergencies described at the top of this page are recognised consequences of that withdrawal. It is why psoriasis is one of the inflammatory skin conditions where a short steroid course is generally avoided, and why a steroid taper prescribed for something else is worth mentioning to whoever manages your skin.

Is anything genuinely new, or is that just marketing?

The recent arrivals are the interesting part here, which is unusual. Two non-steroid creams reached approval in 2022 and are used where steroids cannot be continued. A tablet acting on a single signalling enzyme followed, which matters to anyone who would rather not inject. An antibody aimed at the pustular form was approved for those flares and works within days, in a presentation that previously had nothing developed for it. Tablets aimed at the same targets as the injected drugs are in late-stage trials now. What none of this changes is the shape of this page: every one of them is prescribed.

Building a routine around it

The supporting-care section above describes principles. For a full routine built around very dry, barrier-compromised skin, these start from the same place.

Sources

Everything on this page traces back to the sources below, with the individual trials listed separately above. Psoriasis is unusually well served by guidelines — there is a joint series of them rather than a single document, because the treatment tiers differ enough to warrant separate evidence reviews.

The studies behind this page

The trials behind the specific claims above, beyond the guideline series this page follows. Each was checked against the journal record before it was listed — where a link could not be confirmed you would see the citation without one.

  1. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial) Lebwohl M, Kircik L, Lacour JP, et al. Journal of the American Academy of Dermatology, 2021. The step-down-rather-than-stop advice in 'what happens when it works' — twice-weekly maintenance held remission longer than stopping at clearance.
  2. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis Lebwohl MG, Stein Gold L, Strober B, et al. The New England Journal of Medicine, 2021. The non-steroid topical entries, and the claim that this one is notable for the absence of irritation rather than its presence.
  3. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials Lebwohl MG, Kircik LH, Moore AY, et al. JAMA, 2022. Why the face-and-folds section names this class specifically — results in intertriginous skin were better than on ordinary plaques.
  4. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial Strober B, Thaçi D, Sofen H, et al. Journal of the American Academy of Dermatology, 2023. The newest oral option in the systemic tier, and the year-long comparison it was tested in.
  5. Bimekizumab versus Secukinumab in Plaque Psoriasis Reich K, Warren RB, Lebwohl M, et al. The New England Journal of Medicine, 2021. The statement that complete clearance is now an ordinary trial endpoint rather than an outlier, and the note about agents blocking two members of the IL-17 family.
  6. Trial of Spesolimab for Generalized Pustular Psoriasis Bachelez H, Choon SE, Marrakchi S, et al. The New England Journal of Medicine, 2021. The sentence added to the pustular form: a treatment developed for that presentation, clearing pustules within about a week.
  7. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial Morita A, Strober B, Burden AD, et al. The Lancet, 2023. That the same approach is now used to prevent repeat flares, not only to end one.
  8. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy Yones SS, Palmer RA, Garibaldinos TT, et al. Archives of Dermatology, 2006. The comparison in the phototherapy tier — more people cleared, in fewer sessions, with longer remissions, against a cancer risk that has to be weighed.
  9. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study Kurd SK, Troxel AB, Crits-Christoph P, et al. Archives of Dermatology, 2010. The mental-health association described among the comorbidities, including that it scales with severity.
  10. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis Seité S, Khemis A, Rougier A, et al. Experimental Dermatology, 2009. The one genuinely evidenced claim in the supporting-care section — emollient use after a steroid course helps hold the improvement.

Clinical guidelines

The American Academy of Dermatology and the National Psoriasis Foundation publish these jointly, as a series. No single document covers everything, which is why several are listed.

Patient organisations and information

Written to be read, and in the first case attached to a genuinely useful navigation service.

  • National Psoriasis Foundation — National Psoriasis Foundation (US)

    Patient information, the Seal of Recognition directory, and free one-to-one patient navigation.

  • Psoriasis — NHS (UK)

    Concise, and clear about the referral route through the NHS.

  • Psoriasis — American Academy of Dermatology

    Public-facing overview of types, treatment and self-care.